PIPELINE

GLYCART Product Candidates

GlycoMAb® provides the Company with a unique competitive advantage for developing highly potent antibodies for carefully selected targets. GLYCART’s proprietary pipeline is composed of three different, GlycoMAb®-modified antibodies at the preclinical development stage. In addition, two candidates are undergoing lead optimization. All antibodies are humanized in-house.

GLYCART's pipeline as of June 2005